Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Phase I data presented for ambrisentan in sickle cell disease

Jan. 2, 2020

Phase II data presented for efgartigimod in adults with primary ITP

Dec. 31, 2019

UNC-0638 in combination with HRI knockdown leads to induction of fetal hemoglobin

Dec. 31, 2019

CTI BioPharma presents data from dose-finding PAC203 study of pacritinib

Dec. 31, 2019

Oral compound ameliorates beta-thalassemia

Dec. 30, 2019

Interim data from gene therapy trial confirm BCL11A as therapeutic target in SCD

Dec. 24, 2019

Freeline Therapeutics describes novel next-generation AAV-hFVIII vector candidate

Dec. 23, 2019

Novel mouse models of chronic sustained hypoxia and chronic intermittent hypoxia

Dec. 23, 2019

Sangamo Therapeutics presents preliminary data from phase I/II study of ST-400

Dec. 19, 2019

Hyper-sialylated IgG product M-254 well tolerated in healthy subjects in first-in-human trial

Dec. 18, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Nov. 7, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for November 7, 2024.
Regulatory actions for Oct. 31, 2024
BioWorld
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Capsida, Electra,...
Australia reimburses Vazkepa a decade after US approval
BioWorld
For the first time, Australians have access to CSL Inc.’s Vazkepa (icosapent ethyl/Vascepa) for managing cardiovascular disease more than a decade after the drug...
Sales balloon for GLP-1 drugs from Novo Nordisk, Eli Lilly
BioWorld
Nearly $3.8 billion was earned by Novo Nordisk A/S and Eli Lilly and Co. in the third quarter for their glucagon-like peptide-1 (GLP-1) drugs to treat obesity....

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.